TANDEM DIABETES CARE INC
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
TNDM$18.17+7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference · Provided Herewith | ||||||
|---|---|---|---|---|---|---|
| Exhibit Number · Exhibit Description · Form · File No. · Date of First Filing · Exhibit Number | ||||||
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant (as amended and currently in effect). | 10-Q | 001-36189 | August 3, 2023 | 3.1 | |
| 3.2 | Amended and Restated Bylaws of the Registrant (as amended and currently in effect). | 10-Q | 001-36189 | August 3, 2023 | 3.2 | |
| 10.1 | Settlement, Mutual Release and Cross-License Agreement, dated May 21, 2025, by and between Tandem Diabetes Care, Inc. and F. Hoffmann-La Roche AG | X | ||||
| 10.2 | First Amendment to Settlement, Mutual Release and Cross-License Agreement, dated May 28, 2025, by and between Tandem Diabetes Care, Inc. and F. Hoffmann-La Roche AG | X | ||||
| 31.1 | Certification of John F. Sheridan, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 31.2 | Certification of Leigh A. Vosseller, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.1* | Certification of John F. Sheridan, Chief Executive Officer, pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.2* | Certification of Leigh A. Vosseller, Chief Financial Officer, pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 101.INS | Inline XBRL Instance Document. | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | X | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document contained in Exhibit 101). | X | ||||
| * | This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates it by reference. |
|---|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Tandem Diabetes Care, Inc. | ||
| Dated: August 6, 2025 | By: | /s/ John F. Sheridan |
|---|---|---|
| John F. SheridanPresident and Chief Executive Officer(on behalf of the registrant and as the registrant’sPrincipal Executive Officer) | ||
| Dated: August 6, 2025 | By: | /s/ Leigh A. Vosseller |
| Leigh A. VossellerExecutive Vice President, Chief Financial Officer and Treasurer(Principal Financial and Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.